On Wednesday, Mar. 6, OrthoPediatrics KIDS will release its latest earnings report. Here is Benzinga's outlook for the company based on it's announcement.
Earnings and Revenue
OrthoPediatrics EPS loss is expected to be around 19 cents, according to sell-side analysts. Sales will likely be near $14.22 million.
In the same quarter last year, OrthoPediatrics reported a loss per share of $4.35 on revenue of $11 million. Revenue would be up 21.74 percent from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | -0.11 | -0.14 | -0.3 | -0.17 |
| EPS Actual | -0.15 | -0.21 | -0.41 | -4.35 |
Stock Performance
Over the last 52-week period, shares are up 149.65 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. Analysts generally rate OrthoPediatrics stock as Neutral. The strength of this rating has dwindled over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
